<DOC>
	<DOCNO>NCT01239030</DOCNO>
	<brief_summary>This multi-center parallel study design study efficacy safety fix dos methylphenidate extend release ( ER ) capsule three dose level compare placebo group pediatric patient Attention Deficit Hyperactivity Disorder ( ADHD ) 6 18 year old .</brief_summary>
	<brief_title>Efficacy Safety Methylphenidate HCl ER Capsules Children Adolescents With ADHD</brief_title>
	<detailed_description>This parallel , randomize , double-blind , multi-center , placebo-controlled , force dose , phase 3 study evaluate safety efficacy Biphentin methylphenidate hydrochloride extend release capsule treatment Attention Deficit Hyperactivity Disorder ( ADHD ) pediatric adolescent patient age 6 18 year . The study four phase : ( 1 ) Screening washout ; ( 2 ) Double-blind fix dose study involve test drug 10 , 15 , 20 40 mg/day placebo 1 week ; ( 3 ) Open-label phase include dose optimization dose start 10 mg , allow 60 mg ; ( 4 ) 30-day safety follow-up . Eight ( 8 ) visit may require . The open-label period follow one double-blind fix dose week provide additional opportunity subject receive treatment Biphentin . Extra unscheduled dose optimization visit allow needed additional dose titration visit open-label period . Various safety tolerability , quality life assessment conduct . Biphentin design single daily dose alternative separate dos immediate release methylphenidate provide biphasic plasma profile . It achieve first Cmax similar immediate release methylphenidate . It also come eight ( 8 ) , allow good individualize dosing .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Males female age 6 18 ADHD diagnosis ADHDRSIV score â‰¥ 90th percentile In need treatment ADHD able 2day washout previous medication Females childbearing potential pregnant practice birth control Subject parent/guardian willing comply protocol Signed consent assent IQ le 80 Wechsler Abbreviated Scale Intelligence ( WASI ) Current primary psychiatric diagnosis list disorder Chronic medical illness : seizure , hypertension , thyroid disease , cardiac , family history sudden death , glaucoma Use psychotropic central nervous system ( CNS ) med effect exceed 14 day screen Planned use prohibit drug Is pregnant breastfeed Significant ECG laboratory abnormality Experimental drug medical device within 30 day prior screen Hypersensitivity methylphenidate Inability unwillingness comply protocol Well control current ADHD treatment Inability take oral capsule</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>inattention</keyword>
	<keyword>impulsivity</keyword>
	<keyword>hyperactivity</keyword>
	<keyword>ADHD</keyword>
</DOC>